Akebia Therapeutics, Inc. Appoints Michael Clayman, M.D. And Maxine Gowen, Ph.D. To Its Board Of Directors

Published: Jul 17, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on harnessing the potential of hypoxia-inducible factor (HIF) biology to develop and commercialize novel therapeutics to treat kidney disease, today announced that Michael D. Clayman, M.D., Chief Executive Officer of Flexion Therapeutics, Inc., and Maxine Gowen, Ph.D., President and Chief Executive Officer of Trevena, Inc., have been appointed to the Company’s Board of Directors. In addition, Kim L. Dueholm, Ph.D. will be stepping down from the Board on July 28, 2014, the effective date of Dr. Clayman and Dr. Gowen’s appointments.

Help employers find you! Check out all the jobs and post your resume.

Back to news